Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

April 30, 2018

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01353794 - Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer | Biotech Hunter | Biotech Hunter